NIFTY OUTLOOK: 24050.60    FII 672.09 cr    DII 410.05 cr
(13th April  – 17th April 2026)
As we discussed in the previous report dated 6th April 26 market behaviour remained on the expected lines during the week passed by as interruption of prevailing bearish trend and change of sentiments to bullish take the nifty rally upto 24074.

NIFTY OUTLOOK: 22713.10 FII -9931.13 cr    DII 7208.41 cr
(6th April  – 10th April 2026)
As we discussed in the previous report dated 30th March 26 market behaviour remained on the expected lines during the week passed by as nifty were bounce upto 22941 and from there slide down upto our support of 22210 i.e. made a weekly low of 22182.55.

Date 02.04.2026
NIFTY OUTLOOK: 22679.40 FII -8331.15 cr    DII 7171.80 cr
As discussed yesterday market behaviour remained on the expected lines during the day, as oversold territory on RSI has attract bounce upto 22941.

NIFTY OUTLOOK: 22331.40 FII -11163.06 cr    DII 14894.72 cr
As discussed yesterday market behavior remained on the expected lines during the day, as nifty respected its bearish trend, slip down to day low of 22283.85 and gave closing of 22331.4 i.e.   at our support of 22330.

NIFTY OUTLOOK: 22819.60 FII -4367.30 cr    DII 3566.15 cr
(30th March – 2nd April 2026)
As we discussed in the previous report dated 23rd March 26 market behaviour remained on the expected lines during the week passed by as on Monday 23 Mar 26 nifty start with bearish sentiments which drift down it upto 22471 from there buyers were re strike and nifty were bounce upto 23465. Thus after oscillate both side it gave closing near to its weekly opening i.e. 22819.6.

1. UBS on Coforge
Initiate Neutral, TP Rs 1240
Coforge has consistently delivered strong growth driven by execution, with organic growth of c13-15% over FY24-25 (overall growth of c15-30%)
Estimate revenue CAGR of 15% over FY26-28E
Stock has corrected 35% YTD, with PEG ratio of 0.8x seeming attractive

1. JPMorgan on GLP-1 in India
GLP-1 not an imminent near-term disruption
Anticipate <1% revenue impact in FY28-30 for F&B companies Could affect consumption habits and product preferences Global staples have de-rated in recent years due to low volumes, competition and modern trends Indian consumer companies should adapt product portfolios

UBS on Pharma
Generic GLP-1 likely a highly competitive market; assume sector coverage
Sun Pharma – (Buy) – Looks well-positioned, with innovative medicines and a robust pipeline to support earnings
Cipla – (Neutral) – To face near-term lanreotide supply disruptions, but product launches from late FY27E are healthy

NIFTY OUTLOOK: 223306.45 FII -1805.37 cr    DII 5429.78 cr
As discussed yesterday market behaviour remained on the expected lines during the day, as diminishing selling pressure and interruption to present bearish trend help the bulls to take the nifty rally upto 23465.35.

1. Goldman Sachs On IndiGo
Target Price ₹5200
Earlier Target ₹6000
Recommendation Buy
Believe supply constraints will start to show up over the next few quarters